A two-part, randomised, double-blind, placebo-controlled, parallel-group, 12week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants

Registry ID

2026-525869-42-00

Source registry

CTIS

Status

Authorised

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

Pila Pharma AB

Enrollment

46

Last update

2026-08-13

Conditions

• Diseases [C] - Nutritional and Metabolic Diseases [C18]
• Obesity

Primary outcomes

Frequency, seriousness and intensity of adverse events (AEs)., Clinically significant changes from baseline in vital signs (blood pressure, pulse and body temperature), ECG, clinical laboratory measurements (haematology, clinical chemistry, coagulation) and physical examination findings.

Locations

• , , Sweden

Related clinical trials

• The HENRY trial: testing whether the HENRY parenting programme prevents children from becoming overweight
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
• A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
• Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity
• Safety and Effectiveness of Orbera365™ Intragastric Balloon System

View on source registry